Compare BMRN & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRN | NCLH |
|---|---|---|
| Founded | 1996 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.4B |
| IPO Year | 1999 | 2011 |
| Metric | BMRN | NCLH |
|---|---|---|
| Price | $56.55 | $18.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 17 |
| Target Price | ★ $88.22 | $24.76 |
| AVG Volume (30 Days) | 2.3M | ★ 19.8M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.54 | 0.23 |
| Revenue | $1,313,646,000.00 | ★ $5,396,175,000.00 |
| Revenue This Year | $15.02 | $9.96 |
| Revenue Next Year | $12.23 | $6.60 |
| P/E Ratio | $105.13 | ★ $80.79 |
| Revenue Growth | ★ 17.62 | 10.71 |
| 52 Week Low | $49.26 | $14.53 |
| 52 Week High | $66.28 | $27.18 |
| Indicator | BMRN | NCLH |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 58.11 |
| Support Level | $51.74 | $17.66 |
| Resistance Level | $56.91 | $19.12 |
| Average True Range (ATR) | 1.74 | 0.81 |
| MACD | 0.52 | 0.32 |
| Stochastic Oscillator | 84.40 | 83.18 |
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 17 passenger vessels on order among its brands through 2037, representing 46,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.